Amended Current Report Filing (8-k/a)
07 April 2017 - 6:37AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
(Amendment
No. 1)
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): November 29, 2016
MICROBOT
MEDICAL INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
|
000-19871
|
|
94-3078125
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
5
Hamada Street
Yokneam
2069204 Israel
(Address
of Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code: (908) 938-5561
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
EXPLANATORY
NOTE
On
November 29, 2016, Microbot Medical Inc. (the “Company”) filed with the Securities and Exchange Commission a Current
Report on Form 8-K (the “Original 8-K”) to, among other things, report that the Company entered into a Securities
Exchange Agreement (the “Exchange Agreement”) with Alpha Capital Anstalt (“Alpha Capital”), providing
for the issuance to Alpha Capital by the Company of a convertible promissory note in exchange for (a) the full satisfaction, termination
and cancellation of a secured note of the Company held by Alpha Capital and (b) the release and termination of the first priority
security interest granted thereunder.
The
Exchange Agreement was included as Exhibit 10.2 to the Original 8-K. This Current Report on Form 8-K/A amends the Original 8-K
solely to refile Exhibit 10.2 with the exhibits to the Exchange Agreement referred to therein. Except as otherwise provided herein,
this Current Report on Form 8-K/A does not amend or restate the Original 8-K, nor does it modify or update any of the information
made in the Original 8-K.
Item
9.01
|
Financial
Statements and Exhibits
|
Exhibit
|
|
Description
|
|
|
|
10.2
|
|
Securities
Exchange Agreement between the Company and Alpha Capital Anstalt
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date:
April 6, 2017
|
MICROBOT
MEDICAL INC.
|
|
|
|
|
By:
|
/s/
Harel Gadot
|
|
|
Harel
Gadot, Chairman, President, and
Chief
Executive Officer
|
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2024 to May 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From May 2023 to May 2024